United Therapeutics Corporation last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $832.5 million (+4.1% year over year) and diluted EPS of $5.71. It usually reports 35–56 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 24, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 25, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–56 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
832
+4.1%
|
259
-23.6%
|
5.71
-20.3%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
783
-1.9%
|
333
+7.6%
|
7.27
+13.4%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
782
-1.6%
|
275
-14.7%
|
5.82
-12.2%
|
|
Feb 25, 2026
56 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
790
+7.4%
|
364
+20.9%
|
7.70
+24.0%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
800
+6.8%
|
339
+9.6%
|
7.16
+12.1%
|
|
Jul 30, 2025
30 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
799
+11.7%
|
310
+11.3%
|
6.41
+9.6%
|
|
Apr 30, 2025
30 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
794
+17.2%
|
322
+5.1%
|
6.63
+7.5%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
736
+19.7%
|
301
+38.8%
|
6.21
+43.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UTHR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Silver Spring, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1082554
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.